Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Debt to Equity (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Debt to Equity for 8 consecutive years, with $1.48 as the latest value for Q4 2025.

  • Quarterly Debt to Equity rose 288.08% to $1.48 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.48 through Dec 2025, up 288.08% year-over-year, with the annual reading at $1.48 for FY2025, 288.08% up from the prior year.
  • Debt to Equity for Q4 2025 was $1.48 at Akebia Therapeutics, up from $1.15 in the prior quarter.
  • The five-year high for Debt to Equity was $12.63 in Q4 2022, with the low at -$2.63 in Q1 2023.
  • Average Debt to Equity over 5 years is $1.28, with a median of $0.63 recorded in 2021.
  • The sharpest move saw Debt to Equity skyrocketed 1026.32% in 2022, then crashed 195.17% in 2023.
  • Over 5 years, Debt to Equity stood at $1.32 in 2021, then surged by 858.6% to $12.63 in 2022, then plummeted by 108.98% to -$1.13 in 2023, then skyrocketed by 30.63% to -$0.79 in 2024, then soared by 288.08% to $1.48 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $1.48, $1.15, and $1.61 for Q4 2025, Q3 2025, and Q2 2025 respectively.